0001179110-16-031541.txt : 20161114
0001179110-16-031541.hdr.sgml : 20161111
20161114174946
ACCESSION NUMBER: 0001179110-16-031541
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161109
FILED AS OF DATE: 20161114
DATE AS OF CHANGE: 20161114
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knopf John L
CENTRAL INDEX KEY: 0001586745
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 161996721
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2016-11-09
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586745
Knopf John L
128 SIDNEY STREET
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
2016-11-09
4
M
0
31543
5.88
A
245627
D
Common Stock
2016-11-09
4
M
0
37500
5.28
A
283127
D
Common Stock
2016-11-09
4
M
0
9375
5.28
A
292502
D
Common Stock
2016-11-09
4
M
0
15976
5.28
A
308478
D
Common Stock
2016-11-09
4
M
0
5606
5.08
A
314084
D
Common Stock
2016-11-09
4
S
0
100000
32.19
D
214084
D
Option to Purchase Common Stock
5.88
2016-11-09
4
M
0
31543
0
D
2020-02-04
Common Stock
31543
18457
D
Option to Purchase Common Stock
5.28
2016-11-09
4
M
0
37500
0
D
2021-12-16
Common Stock
37500
12500
D
Option to Purchase Common Stock
5.28
2016-11-09
4
M
0
9375
0
D
2022-11-13
Common Stock
9375
28125
D
Option to Purchase Common Stock
5.28
2016-11-09
4
M
0
15976
0
D
2022-11-13
Common Stock
15976
21524
D
Option to Purchase Common Stock
5.08
2016-11-09
4
M
0
5606
0
D
2018-03-27
Common Stock
5606
109027
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.98, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
The options of registrant's common stock vested over three years, with the first vesting three months after the achievement of the appropriate performance trigger. If the performance trigger was not achieved, the options vested on the four year anniversary of the grant.
/s/ John D. Quisel, as attorney-in-fact for John L. Knopf
2016-11-14